Cencora, Inc.

NYSE:COR Rapport sur les actions

Capitalisation boursière : US$46.6b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Cencora Croissance future

Future contrôle des critères 2/6

Cencora devrait augmenter ses bénéfices et son chiffre d'affaires de 11.3% et de 6.9% par an respectivement. Le BPA devrait croître de de 14% par an. Le rendement des capitaux propres devrait être 98.7% dans 3 ans.

Informations clés

11.3%

Taux de croissance des bénéfices

14.0%

Taux de croissance du BPA

Healthcare croissance des bénéfices19.3%
Taux de croissance des recettes6.9%
Rendement futur des capitaux propres98.6%
Couverture par les analystes

Good

Dernière mise à jour21 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings

Jul 16
Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings

Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning

Jun 30

Are Investors Undervaluing Cencora, Inc. (NYSE:COR) By 43%?

Jun 28
Are Investors Undervaluing Cencora, Inc. (NYSE:COR) By 43%?

Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly

Jun 09
Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly

Do Cencora's (NYSE:COR) Earnings Warrant Your Attention?

May 21
Do Cencora's (NYSE:COR) Earnings Warrant Your Attention?

Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings

Apr 05
Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings

Cencora Remains Chronically Undervalued, With Material Growth Potential

Mar 25

Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price

Mar 18
Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price

Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly

Feb 25
Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly

Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Feb 07
Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price

Jan 05
Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price

Cencora: Continued Economic Value On The Table Across All Investment Horizons

Jan 04

A Look At The Fair Value Of Cencora, Inc. (NYSE:COR)

Dec 15
A Look At The Fair Value Of Cencora, Inc. (NYSE:COR)

Cencora (NYSE:COR) Is Paying Out A Larger Dividend Than Last Year

Nov 05
Cencora (NYSE:COR) Is Paying Out A Larger Dividend Than Last Year

Is Cencora (NYSE:COR) A Risky Investment?

Nov 03
Is Cencora (NYSE:COR) A Risky Investment?

Cencora: New Name, Same Old Economic Leverage, Reiterate Buy

Oct 18

AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 34% Below Their Intrinsic Value Estimate

Aug 01
AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 34% Below Their Intrinsic Value Estimate

AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)

Jul 28

We Think AmerisourceBergen (NYSE:ABC) Can Stay On Top Of Its Debt

Jun 19
We Think AmerisourceBergen (NYSE:ABC) Can Stay On Top Of Its Debt

Is AmerisourceBergen Corporation (NYSE:ABC) Trading At A 28% Discount?

May 01
Is AmerisourceBergen Corporation (NYSE:ABC) Trading At A 28% Discount?

Here's Why We Think AmerisourceBergen (NYSE:ABC) Is Well Worth Watching

Apr 10
Here's Why We Think AmerisourceBergen (NYSE:ABC) Is Well Worth Watching

AmerisourceBergen (NYSE:ABC) Has A Pretty Healthy Balance Sheet

Mar 02
AmerisourceBergen (NYSE:ABC) Has A Pretty Healthy Balance Sheet

AmerisourceBergen declares $0.485 dividend

Feb 01

AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 25% Below Their Intrinsic Value Estimate

Jan 28
AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 25% Below Their Intrinsic Value Estimate

AmerisourceBergen partners with pharmaceutical company Civica

Jan 23

AmerisourceBergen: What Does The Valuation Look Like After The Recent Price Rise?

Jan 13

Does AmerisourceBergen (NYSE:ABC) Deserve A Spot On Your Watchlist?

Jan 10
Does AmerisourceBergen (NYSE:ABC) Deserve A Spot On Your Watchlist?

AmerisourceBergen sued by DoJ over suspicious opioid orders

Dec 29

Prévisions de croissance des bénéfices et des revenus

NYSE:COR - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
9/30/2026334,1442,5303,3453,89814
9/30/2025313,4742,2742,8833,44315
9/30/2024292,6092,0302,6263,05914
6/30/2024283,8311,8563,8314,311N/A
3/31/2024276,5371,8522,1122,578N/A
12/31/2023271,5791,8673,6304,086N/A
9/30/2023262,1731,7453,4533,911N/A
6/30/2023254,4251,6892,7933,249N/A
3/31/2023247,5431,6172,4472,913N/A
12/31/2022241,8051,7292,0572,550N/A
9/30/2022238,5871,6992,2072,703N/A
6/30/2022236,3251,8422,0612,548N/A
3/31/2022229,6661,7272,8513,347N/A
12/31/2021221,1011,6142,1742,627N/A
9/30/2021213,9891,5402,2282,667N/A
6/30/2021204,321-3,7442,5642,956N/A
3/31/2021196,282-3,7471,2841,660N/A
12/31/2020194,546-3,2222,6002,967N/A
9/30/2020189,894-3,4091,8372,207N/A
6/30/2020186,2871,5701,2501,581N/A
3/31/2020186,1591,5821,9432,236N/A
12/31/2019182,0616491,7102,008N/A
9/30/2019179,5898552,0342,344N/A
6/30/2019177,2489562,0182,337N/A
3/31/2019175,1519302,2632,592N/A
12/31/2018172,8661,1901,5381,880N/A
9/30/2018167,9401,6581,0751,411N/A
6/30/2018163,7631,0811,7832,126N/A
3/31/2018159,327855N/A1,059N/A
12/31/2017155,441979N/A1,945N/A
9/30/2017153,144364N/A1,504N/A
6/30/2017151,584855N/A1,478N/A
3/31/2017149,7591,154N/A1,915N/A
12/31/2016148,3101,346N/A1,997N/A
9/30/2016146,8501,428N/A3,178N/A
6/30/2016144,7591,643N/A2,986N/A
3/31/2016142,1111,508N/A3,916N/A
12/31/2015139,082391N/A3,777N/A
9/30/2015135,962-138N/A3,922N/A
6/30/2015132,080-431N/A3,591N/A
3/31/2015128,195-658N/A2,989N/A
12/31/2014123,98135N/A3,364N/A
9/30/2014119,569282N/A1,465N/A
6/30/2014112,449267N/A602N/A
3/31/2014104,008344N/A157N/A
12/31/201396,076368N/A26N/A
9/30/201387,959493N/A788N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de COR ( 11.3% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de COR ( 11.3% par an) devraient croître plus lentement que le marché US ( 15.1% par an).

Croissance élevée des bénéfices: Les bénéfices de COR devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de COR ( 6.9% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de COR ( 6.9% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de COR devrait être très élevé dans 3 ans ( 98.7 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y